article thumbnail

Treatment of Metastatic Triple-Negative Breast Cancer

The Pharma Data

Food and Drug Administration (FDA) to treat adult patients with metastatic TNBC who have received at least two prior therapies for metastatic disease. Premedicate with a 2- or 3-drug combination regimen (e.g., SG (under the tradename Trodelvy ® ) received accelerated approval by the U.S. Embryo-Fetal Toxicity.

article thumbnail

FIRST-LINE IBRANCE® (PALBOCICLIB) COMBINATION THERAPY IN HR+, HER2- METASTATIC BREAST CANCER

The Pharma Data

Food and Drug Administration more than six years ago, IBRANCE has been prescribed to more than 380,000 patients across more than 100 countries. IBRANCE may impair fertility in males and has the potential to cause genotoxicity. OS data is being collected in the PALOMA-2 randomized clinical trial but is not yet mature.

HR 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

The Pharma Data

Food and Drug Administration (FDA) has granted full approval to Trodelvy ® (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. DRUG INTERACTIONS.

HR 52
article thumbnail

Trodelvy® for the Treatment of Metastatic Urothelial Cancer

The Pharma Data

The FDA’s accelerated approval mechanism enables drugs that treat serious diseases with unmet medical need to be approved based on a surrogate or intermediate clinical endpoint. Premedicate with a two or three drug combination regimen (e.g., TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells.

article thumbnail

Accelerating NDA filing through faster carcinogenicity assessment

Drug Discovery World

Dr Megan MacBride and Dr Caroline Horizny Mitchell , Taconic, examine recent changes to animal testing in drug design. Drug discovery and development is an arduous process that can cost upwards of $2.6 In August 2022, the ICH issued an addendum to its S1B guidelines that allows certain drugs to forego two-year rat studies 1.

article thumbnail

Let's Quit Sugar With Audiobook – Let's Quit Sugar

The Pharma Data

Following this program will help you lose weight fast, prevent yo-yoing, stabilize hormonal balance, and get back on track to leading a healthy life – all while never being hungry or having to go to the gym! Effects of glucose-to-fructose ratios in solutions on subjective satiety, food intake, and satiety hormones in young men.

Insulin 52